Where is the next Chinese drug that will make MNCs compete to grab orders?
HONG KONG, Jan 9, 2025 – (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently, Candid Therapeutics, an American pharmaceutical company focusing on the field of autoimmunity, announced three R&D cooperation transactions on TCE bispecific antibodies with a total potential transaction
HONG KONG, Jan 9, 2025 – (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently, Candid Therapeutics, an American pharmaceutical company focusing on the field of autoimmunity, announced three R&D cooperation transactions on TCE bispecific antibodies with a total potential transaction amount of over $1.32 billion…
Read More
About Author
